SEARCH

SEARCH BY CITATION

References

  • 1
    Nordwall M, Arnqvist HJ, Bojestig M, Ludvigsson J. Good glycemic control remains crucial in prevention of late diabetic complications – the Linkoping Diabetes Complications Study. Pediatr Diabetes 2009: 10: 168172.
  • 2
    DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977986.
  • 3
    DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994: 125: 177188.
  • 4
    Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994: 330: 1518.
  • 5
    Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Linköping Diabetes Complications Study. Declining incidence of severe retinopathy and persisting decrease of nephopathy in an unselected population of type 1 diabetes - the Linkoping Diabetes Complications Study. Diabetologia 2004: 47: 12661272.
  • 6
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS). Lancet 1998: 352: 854865.
  • 7
    Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997: 20: 2225.
  • 8
    Bjørgaas MR. Cerebral effects of severe hypoglycaemia in young people with type 1 diabetes. Pediatr Diabetes 2012: 13: 100107.
  • 9
    Ho MS, Weller NJ, Ives FJ et al. Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. J Pediatr 2008: 153: 385390.
  • 10
    Lunetta M, Damanti AR, Fabbri G, Lombardo M, Di Mauro M, Mughini L. Evidence by magnetic resonance imaging of cerebral alterations of atrophy type in young insulin-dependent diabetic patients. J Endocrinol Invest 1994: 17: 241245.
  • 11
    Perros P, Deary IJ, Sellar RJ, Best JJ, Frier BM. Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia. Diabetes Care 1997: 20: 10131018.
  • 12
    Ryan C, Gurtunca N, Becker D. Hypoglycemia: a complication of diabetes therapy in children. Pediatr Clin North Am 2005: 52: 17051733.
  • 13
    Barnard K, Thomas S, Royle P, Noyes K, Waugh N. Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. BMC Pediatr 2010: 10: 50.
  • 14
    Davis NL, Bursell JD, Evans WD, Warner JT, Gregory JW. Body composition in children with type 1 diabetes in the first year after diagnosis: relationship to glycaemic control and cardiovascular risk. Arch Dis Child 2012: 97: 312315.
  • 15
    Hanberger L, Samuelsson U, Berterö C, Ludvigsson J. The influence of structure, process, and policy on HbA1c levels in treatment of children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2012: 96: 331338.
  • 16
    Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008: 25: 442449.
  • 17
    Russell-Jones D, Bolinder J, Simpson R. Lower and more predictable fasting blood glucose and reduced risk of nocturnal hypoglycaemia with once daily insulin detemir versus NPH in subjects with type 1 diabetes. Diabetologia 2002: 45 (Suppl. 1): A51.
  • 18
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005: 7: 5664.
  • 19
    Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003: 26: 590596.
  • 20
    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007: 24: 2734.
  • 21
    Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V. Treatment with insulin detemir or NPH insulin in children aged 2–5 yr with type 1 diabetes mellitus. Pediatr Diabetes 2011: 12: 632641.
  • 22
    Lüddeke HJ, Sreenan S, Aczel S et al, PREDICTIVE Study Group. PREDICTIVE™ – a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007: 9: 428434.
  • 23
    Sreenan S, Virkamäki A, Zhang K, Hansen JB. PREDICTIVE study group. Switching from NPH insulin to once-daily insulin detemir in basal–bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE™ study. Int J Clin Pract 2008: 62: 19711980.
  • 24
    Dornhorst A, Lüddeke HJ, Honka M et al, PREDICTIVE Study Group. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin 2008: 24: 369376.
  • 25
    Karlberg J, Luo ZC, Albertsson-Wikland K. Body mass index reference values (mean and SD) for Swedish children. Acta Paediatr 2001: 90: 14271434.
  • 26
    Kurtoglu S, Atabek ME, Dizdarer C et al. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE™ observational study. Pediatr Diabetes 2009: 10: 401407.
  • 27
    Silverstein J, Klingensmith G, Copeland K et al, American Diabetes Association. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005: 28: 186212.
  • 28
    Global IDF/ISPAD guideline for diabetes in childhood and adolescence. 2011 (available from http://www.ispad.org/NewsFiles/IDF-ISPAD_Diabetes_in_Childhood_and%20Adolescence_Guidelines_2011.pdf). Accessed on 14 November 2012.
  • 29
    Rosenstock J, Davies M, Home PD, Jarsen J. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as an add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia 2008: 51: 408416.
  • 30
    Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V. Insulin analogues in children with type 1 diabetes: a 52-week randomized clinical trial. Diabet Med 2013: 30: 216225.
  • 31
    Cryer PE. Hypoglycemia: the limiting factor in the glycaemic management of type 1 and type II diabetes. Diabetologia 2002: 45: 937948.